特納亞治療公司
US ˙ NasdaqGS ˙ US87990A1060

SecurityTNYA / Tenaya Therapeutics, Inc.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership2,732,800 shares
Ownership 1.70%
BlackRock, Inc. ownership in TNYA / Tenaya Therapeutics, Inc.

2025-07-16 - BlackRock, Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,732,800 shares of Tenaya Therapeutics, Inc. (US:TNYA). This represents 1.7 percent ownership of the company. In their previous filing dated 2025-02-05 , BlackRock, Inc. had reported owning 5,296,476 shares, indicating a decrease of -48.40 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-07-16 2025-07-16 13G/A 5,296,476 2,732,800 -48.40 1.70 -74.63
2025-02-05 2025-02-05 13G/A 3,786,824 5,296,476 39.87 6.70 19.64
2024-01-31 2024-01-31 13G 3,786,824 5.60

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F TENAYA THERAPEUTICS COM 87990A106 3,703,955 -244,631 -6.20 2,565 -8.72 0.0000
2026-02-12 2025-12-31 13F TENAYA THERAPEUTICS COM 87990A106 3,948,586 1,621,385 69.67 2,809 -25.49 0.0000
2025-11-12 2025-09-30 13F TENAYA THERAPEUTICS COM 87990A106 2,327,201 -405,599 -14.84 3,770 125.75 0.0001
2025-08-12 2025-06-30 13F TENAYA THERAPEUTICS COM 87990A106 2,732,800 -2,523,802 -48.01 1,670 -44.26 0.0000
2025-05-02 2025-03-31 13F TENAYA THERAPEUTICS COM 87990A106 5,256,602 -39,874 -0.75 2,997 -60.44 0.0001
2025-02-07 2024-12-31 13F TENAYA THERAPEUTICS COM 87990A106 5,296,476 1,190,171 28.98 7,574 -4.44 0.0002
2024-11-13 2024-09-30 13F TENAYA THERAPEUTICS COM 87990A106 4,106,305 32,249 0.79 7,925 -37.25 0.0002
2024-08-13 2024-06-30 13F TENAYA THERAPEUTICS COM 87990A106 4,074,056 -626,941 -13.34 12,630 -48.63 0.0003
2024-05-10 2024-03-31 13F TENAYA THERAPEUTICS COM 87990A106 4,700,997 914,173 24.14 24,586 100.39 0.0006
2024-02-13 2023-12-31 13F TENAYA THERAPEUTICS COM 87990A106 3,786,824 -896,343 -19.14 12,269 2.74 0.0003
2023-11-13 2023-09-30 13F TENAYA THERAPEUTICS COM 87990A106 4,683,167 1,047,019 28.79 11,942 -44.05 0.0003
2023-08-11 2023-06-30 13F TENAYA THERAPEUTICS COM 87990A106 3,636,148 850,661 30.54 21,344 168.88 0.0006
2023-05-12 2023-03-31 13F TENAYA THERAPEUTICS COM 87990A106 2,785,487 524,792 23.21 7,939 74.73 0.0002
2023-02-13 2022-12-31 13F TENAYA THERAPEUTICS COM 87990A106 2,260,695 -180,686 -7.40 4,544 -35.82 0.0001
2022-11-14 2022-09-30 13F TENAYA THERAPEUTICS COM 87990A106 2,441,381 -21,548 -0.87 7,079 -48.95 0.0002
2022-08-12 2022-06-30 13F TENAYA THERAPEUTICS COM 87990A106 2,462,929 34,057 1.40 13,866 -51.54 0.0004
2022-05-12 2022-03-31 13F TENAYA THERAPEUTICS COM 87990A106 2,428,872 555,928 29.68 28,611 -19.39 0.0008
2022-02-10 2021-12-31 13F TENAYA THERAPEUTICS COM 87990A106 1,872,944 253,225 15.63 35,493 6.11 0.0009
2021-11-09 2021-09-30 13F TENAYA THERAPEUTICS COM 87990A106 1,619,719 1,619,719 33,448 0.0009
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.